NICE gives thumbs-up to Pfizer's migraine drug—but with lots of restrictions

Biohaven had little trouble gaining approval in the U.S. and the EU for its migraine medicine Nurtec (rimegepant), as regulators have signed off on the medicine to both treat and prevent attacks.